Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Growing Insecurity Forces MSF To Leave Its Largest Health Center In Somalia
After nine years of providing health care for the population in Bakool region, Doctors Without Borders/Mç©decins Sans Frontiç¨res (MSF) has reached the regrettable conclusion that it does not have sufficient security to continue its work. This decision was MSF"s alone and the organization was not expelled by the authorities. MSF medical activities elsewhere in Somalia continue.

Nine New Innovative Collaborations To Receive Funding From UTSA
In February 2009, the Office of the Vice President of Research at UTSA announced it would offer approximately $242,000 through its Collaborative Research Seed Grant Program (CRSGP) and its Tenure-track Research Award Competition (TRAC). The programs help UTSA faculty establish new, innovative, collaborative and multidisciplinary research programs in one or more of UTSA"s five strategic areas of excellence: health, security, energy and the environment, human and social development, and sustainability.
News of the day
Statement By Merck & Co., Inc. Regarding FOSAMAX® (alendronate Sodium) And Rare Cases Of Osteonecrosis Of The Jaw
Merck is committed to putting patients first and providing accurate information regarding the efficacy, safety and tolerability of our medicines. Merck offers the following statement concerning the osteoporosis medication FOSAMAX® (alendronate sodium) and reports of jaw problems associated with delayed healing and infection of the jaw often following tooth extraction. The condition is known as osteonecrosis of the jaw (ONJ).
Sexual Health

New Device For Liver Cancer Cleared

Acculis Limited, the UK based specialist microwave ablation company based in Denmead, England, announced the clearance of its latest device for coagulating and killing unwanted tissue during surgery. The device, designed for coagulations at the surface of the tissue fires controlled high power microwave energy into the target area causing it to heat rapidly and the cells to die. Liver surgeons around the world are using the Acculis MTA System to address tumours inside the liver using its existing needle probes that take the microwave energy to the centre of tumours. Using the same control unit, this latest device allows surgeons to address deposits on the surface of the liver without using a needle. David Lloyd, consultant surgeon from Leicester Royal Infirmary, worked with Professor Nigel Cronin on the device which was also used by consultant HPB surgeons Graeme Poston, Liverpool Aintree and David Sherlock, North Manchester General during the development phase under MHRA control. "During development we used the device to treat patients with multiple surface tumours quickly and decisively. There is no other high-tech device available in the market which can coagulate as quickly and as deeply as the Acculis Surface Applicator. It is extremely useful in patients with multiple tumours which are non-resectable. For example I successfully treated a patient with severe symptoms relating to more than 40 liver tumours using both this surface device and the high power needle. It is an important addition to our capability alongside the existing high power microwave needle probes." commented Lloyd. The device will now be made available for patients in the UK and Europe under the CE mark at centres already employing the Acculis MTA System. These include Edinburgh Royal Infirmary, North Hants Hospital Basingstoke as well as the Leicester Royal, Liverpool Aintree and North Manchester General. The device will be distributed by Acculis" sister company Microsulis Medical Limited. "The Acculis MTA System is a groundbreaking system for the inter-operative coagulation of tissue. Focussed and controlled high power microwave energy kills the target cells very rapidly by quickly raising their temperature while blood flowing around the outside of the target area keeps adjacent tissue cool. The simplicity of the system also allows surgeons and staff to focus on the treatment rather than on managing complex control and generator systems. We are delighted to add this new device to the range." said Acculis and Microsulis Managing Director, Stuart McIntyre. Acculis is a specialist medical device company developing microwave energy ablation systems for oncology applications. Acculis is part of the Microsulis group of companies. Microsulis and Acculis are based in Hampshire, England. For more information about the Acculis MTA System, visit http://www.acculis.com, http://www.microsulis.com. Acculis


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009